J. Clin. Invest. 1993, 91, 397-401
382 HIRATA K., KIKUCHI S., SAKU K., JIMI S., ZHANG B. et
al
Apolipoprotein(a) phenotypes and serum lipoprotein(a)
levels in maintenance hemodialysis patients with/without diabetes
mellitus.
Kidney Int. 1993, 44, 1062-1070
383 KRONENBERG F., KONIG P., NEYER U., AUINGER M.,
PRISBANIG A., et al.
Multicenter study of lipoprotein(a) and apolipoprotein(a)
phenotypes in patients with end-stage renal disease treated by hemodialysis or
continuous ambulatory peritoneal dialysis.
J. Am. Soc. Nephrol. 1995, 6, 110-120
384 BLACK I., WILCKEN D.
Decreases in apolipoprotein(a) after renal
transplantation: implications for lipoprotein(a) metabolism. Clin. Chem. 1992,
38, 353-357
385 KRONENBERG F., KONIG P. LHOTTA K., OFNER D.,
SANDHOLZER C. et al
Apolipoprotein(a) phenotype-associated decrease in
lipoprotein(a) plasma concentrations after renal transplantation.
Arterioscler. Thromb. 1994, 14, 1399-1404
386 HILBRANDS L.B., DEMACKER P.N., HOITSMA A.J.
Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993, 341,
765
387 AZROLAN N., BROWN C., THOMAS L., HAYEK T., ZHAO A.,
et al
Cyclosporin A has divergent effects on plasma LDL
cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) levels in renal transplant
recipients. Evidence for renal involvement in the maintenance of LDL-C and the
elevation of Lp(a) concentrations in hemodialysis patients.
Arterioscler. Thromb. 1994, 14, 1393-1398
Thèse Docteur Pharmacie La lipoprotéine Lp(a) :
son intérêt dans l'interprétation du bilan lipidique Dr
GUIMONT MC 269/271 Lipides, Lipoprotéine (a),
Hyperlipoprotéinémie, Athérosclérose, Lipids,
Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis
Thèse Docteur Pharmacie La lipoprotéine Lp(a) :
son intérêt dans l'interprétation du bilan lipidique Dr
GUIMONT MC 270/271 Lipides, Lipoprotéine (a),
Hyperlipoprotéinémie, Athérosclérose, Lipids,
Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis
388 SEGARRA A., CHACON P., MARTIN M.,
VILARDELL M., VILA J. et al
Serum lipoprotein(a) levels in patients with chronic
renal failure. Evolution after renal transplantation and relationship with
other parameters of lipoprotein metabolism: a prospective study.
Nephron 1995, 69, 9-13
389 KRONENBERG F., KATHREIN H., KONIG P., NEYER U., STURM
W et al.
Apolipoprotein(a) phenotypes predict the risk for carotid
atherosclerosis in patients with end-stage renal disease.
Arterioscler. Thromb. 1994, 14, 1405-1411
399 DE BRUIN T., VAN BARLINGEN H., VAN LINDESIBENIUS M.,
VAN VUURST DE VRIES A. et al. Lipoprotein(a) and apolipoproteinB plasma
concentrations in hypothyroid, euthyroid, and hyperthyroid
subjects.
Clin. Endocrinol. Metab. 1993, 76, 121-126
391 ENGLER H., RIESEN W.
Effect of thyroid function on concentrations of
lipoprotein(a). Clin. Chem. 1993, 39, 2466-2469
392 WANG A., PANG R., LAUDER I., LAM K., JANUS
E.
Changes in serum lipoprotein(a) and lipids during
treatment of hyperthyroidism. Clin. Chem. 1995, 41, 226-231
393 KLAUSEN L.C., HEGEDUS L., HANSEN P.S., NIELSEN F.E.,
GERDES L.U. et al. Apolipoprotein(a) phenotypes and lipoprotein(a)
concentrations in patients with hyperthyroidism. J. Mol. Med. 1995, 73,
41-46
394 TAKAHASHI S., YAMAMOTO T., MORIWAKA Y., TSUTSUMI Z.,
HIGASHINO K. Increased concentrations of serum Lp(a) lipoprotein in patients
with primary gout. Ann. Rheum. Dis. 1995, 54, 90-93
395 GREGORY W., GAME F., FARRER M., IDLE J., LAKER M. et
al.
Reduced serum lipoprotein(a) levels in patients with
primary biliary cirrhosis. Atherosclerosis 1994, 105, 43-50
396 ALESSANDRI C., BASIL! S., MAURELLI M., ANDREOZZI P.,
VIOL! F. et al.
Relatioship between lipoprotein(a) levels in serum and
some indices of protein synthesis in liver cirrhosis.
Clin. Chim. Acta 1994, 224, 125-129
397 GEISS H.C., RITTER M.M., RICHTER W.O.,
SCHWANDT P., ZACHOVAL R. Low lipoprotein(a) levels during acute viral
hepatitis.
Hepatology 1996, 24, 1334-1337
398 RANTAPAA-DAHLQVIST S., WALLBERG-JONSSON S., DAHLEN G.
Lipoprotein(a), lipids, and lipoproteins in pateints with rheumatoid arthritis.
Ann. Rheum. Dis. 1991, 50, 366-368
399 OKAWA-TAKATSUJI M., AOTSUKA S., SUMIYA M.,
OHTA H. KAWAKAMI M. et al.
Clinical significance of serum lipoprotein(a) level in
patients with systemic lupus erythematosus: its elevation during disease
flare.
Clin. Experim. Rheumatol. 1996, 14, 531-536
400 BACHORIK P.S., ROSS J.W., For the N C E P Working
Group on Lipoprotein Measurement. National Cholesterol Education
ProgramRecommandations for measurement of Low-Density Lipoprotein Cholesterol :
exectutive summary.
Clin. Chem. 1995, 41, 1414-1420
401 COOPER G.R., MYERS G.L., SMITH S.J., SCHLANT R.C.
Blood lipid measurements. Variations and practical utility. JAMA 1992, 267,
1652-1660
402 SMITH S.J., COOPER G.R., MYERS G.L., SAMPSON
E.J.
Biological variability in concentrations of serum lipids:
Sources of variation among results from published studies and composite
predicted values.
Clin. Chem. 1993, 39, 1012-1022
403 BOYER H., DE GENNES J-L., TRUFFERT J., CHATELLIER G.,
DAIROU F. et al. Lpa(a) levels in different types of dyslipidemia in the French
population.
Atherosclerosis, 1990, 85, 61-69
404 RITTER M.M., GEISS H.C., RICHTER W.O., SCHWANDT
P.
Lipoprotein(a) concentrations and phenotypes in controls
and patients with hypercholesterolemia or hypertriglyceridemia.
Metabolism 1994, 43, 572-578
405 BARTENS W., RADER D.J., TALLEY G., BREWER H.B.
Lipoprotein(a) in patients with hyperlipidaemia.
Eur. J. Clin. Invest. 1995, 25, 647-653
406 ELISAF M.S., BAIRAKTARI
E.T., TZALLAS C.S., SIAMOPOULOS K.C. Lipoprotein(a) concentrations in patients
with various dyslipidaemias. Ann. Med. 1997, 29, 305-309
407 HIRAGA T., OKUBO M., KOBAYASHI T., NAKANISHI K.,
SUGIMOTO T. et al. Serum lipoprotein(a) levels in differents phenotypes of
primary hyperlipoproteinemia. Metabolism 1993, 42, 1327-1330
408 PANTEGHINI M., PAGAN! F.
Pre-analytical, analytical and biological sources of
variation of lipoprotein(a). Eur. J. Clin. Chem. Clin. Biochem. 1993, 31,
23-28
KRONENBERG F., TRENKWALDER E., DIEPLINGER H., UTERMANN
G.
Lipoprotein(a) in stored plasma samples and ravages of
time. Why epidemiological studies might fail. Arterioscler. Thromb. Vasc. Biol.
1996, 16, 1568-1572
410 SEMAN L., DeLUCA C., WILSON P., ORDOVAS J., SCHAEFER
E.
Plasma lipoprotein(a) cholesterol, normal ranges and
relationship to coronary heart disease : results from the Framingham Offspring
Study.
Clin. Chem. 1997, 43, S266-S267
411 ROSENSON R.S.
Beyond low-density lipoprotein cholesterol.
A perspective on low high-density lipoprotein disorders
and Lp(a) lipoprotein excess.
Arch. Intern. Med. 1996, 156, 1278-1284
412 BERG K.
Unchanged serum lipoprotein(a) concentrations with
lovastatin. Lancet, 1989;_, 812-813
413 SLUNGA L., DAHLEN G.H.
Changes in Lp(a) lipoprotein levels during the treatment
of hypercholesterolaemia with simvastatin. Eur. J. Clin. Pharmacol. 1992, 43,
369-373
414 O'CONNOR P., COOKE T., FEELY J.
Effects of HMG Co-A reductase inhibitors on lipids and
lipoprotein(a) in hypercholesterolaemia. Drug. Invest. 1992, 4,
227-231
415 LEREN T.P., HJERMANN I., FOSS O.P., LEREN P., BERG
K.
Long-term effect of lovastatin alone or in combiantion
with cholestyramine on lipoprotein(a) level in familial hypercholesterolemic
subjects.
Clin. Invest. 1992, 70, 711-718
Thèse Docteur Pharmacie La lipoprotéine Lp(a) :
son intérêt dans l'interprétation du bilan lipidique Dr
GUIMONT MC 271/271 Lipides, Lipoprotéine (a),
Hyperlipoprotéinémie, Athérosclérose, Lipids,
Lipoprotein, Lpa, Hyperlipoproteinemia, Atherosclerosis
416 KOSTNER G., GAVISH D., LEOPOLD B., BOLZANO K.,
WEINTRAUB M., BRESLOW J. HMG CoA reductase inhibitors lower LDL cholesterol
without reducing Lp(a) levels.
Circulation 1989, 80, 1313-1319
417 BRANCH! A., ROVELLINI A.,
FIORENZAA.M., SOMMARIVA D.
Effects of bezafibrate and of 2 HMG-CoA redustase
inhibitors on lipoprotein(a) levels in hypercholesterolemic
patients.
Int. J. Clin. Pharmacol. Therap. 1995, 33,
345-350
418 JONES P.H., POWNALL H.J.,
PATSCH W., HERD J.A., FARMER J.A. et al.
Effect of gemfibrozil on levels of lipoprotein(a) in type
II hyperlipoproteinemic subjects. J. Lipid Res. 1996, 37, 1298-1308
416 GURAKAR A., HOEG J., KOSTNER G., PAPADOPOULOS N.,
BREWER H. Levels of lipoprotein(a) decline with neomycin and niacin
treatment.
Atherosclerosis, 1985, 57, 293-301
42° CARLSON L., HAMSTEN A., ASPLUND A.
Pronounced lowering of serum levels of lipoprotein(a) in
hyperlipidaemic subjects treated with nicotinic acid.
| 
